Cancer and Tobacco Awareness Program at IOCL on WCD 2024

On February 2, 2023, a Cancer and Tobacco Awareness Program was conducted for the workers of Indian Oil Corporation Limited (IOCL), Mathura, on the occasion of World Cancer Day 2024. The program was organized by MAX Institute of Cancer Care, Vaishali, in association with IOCL, Mathura.

The chief speaker of the program was Dr. Pawan Gupta, M.Ch., Sr. Director, MAX Institute of Cancer Care, Vaishali, who is a renowned oncologist and an expert in tobacco cessation. He was honored by Mr. Vikram Phuleriya, DGM Marketing, IOCL, Mathura, who presented him with a memento and thanked him for his valuable service. The program was coordinated by Mr. Sonu Patel, Safety Officer, IOCL, Mathura, and doctors Dr. Pronita Banerjee and Dr. Pradyuman Kaushik. MAX was represented by Mr. Sachin Bhatia and Mr. Lalit Kumar.

The program was attended by 45 workers of IOCL, Mathura, who actively participated in the interactive session. Dr. Pawan Gupta talked about cancer and its prevention, emphasizing tobacco as the main cause. He showed a video presentation that illustrated how harmful tobacco is to the health and well-being of the users and their families. He informed the workers that tobacco is responsible for more than 50% of the 16 types of cancers that are known to be caused by it. He also explained the various signs and symptoms of oral cancer, such as white patches, red patches, nodules, ulcers, or pigmentation in the oral cavity. He urged the workers to do a self-oral examination and look for any abnormality or lesion in their mouth. He demonstrated a simple four-finger mouth-opening test and found that seven of the workers had a mouth opening of fewer than two fingers, which is alarming and needs intervention. He warned the workers that oral premalignant lesions, if not treated at the right time, have a 70% chance of becoming cancerous.

Knowing this it created a fear in the minds of the workers taking tobacco!

Dr. Gupta also talked about the advancements in medical science and the availability of effective treatment for tobacco cessation. He said that specific medicines are given to each individual, based on their assessment and monitoring, and the treatment usually lasts for three to six months. He added that some people may need two or three attempts before they can quit tobacco completely. He encouraged the workers to seek professional help and support to quit tobacco and improve their quality of life.

During the interaction, Dr Gupta asked the following questions to the participants –

1.      How many of them were taking tobacco of any form-

a.      37 responded by raising their hands

2.      How many have never taken tobacco in their lifetime

a.      7 never took tobacco any time in life

3.      How many do yoga or exercise

a.      No one did yoga or exercise or meditation

4.      Amongst the tobacco users, How many knew that tobacco is bad

a.      100% new tobacco is bad

5.      How many have attempted to quit tobacco any time in life

a.      32 of 37 have tried but failed

6.      How many wished to quit tobacco

a.      46 of 47 wished to quit tobacco

7.      After explaining that it is possible to quit tobacco through medical means specific medications are available and it is done with scientific protocol-based methodology all of the workers were eager to quit tobacco and wished such a facility was provided to them.

8.      How many are ready to pay for their treatment but want to quit – 100% were ready for the same.

9.      7 of the workers had decreased mouth opening and needed immediate intervention.

Tobacco users were suggested to do a self-oral examination and look for Chota Daana in the oral cavity which can be in the form of a white patch, red patch, nodule, ulcer, or just pigmentation. A simple 4 finger mouth opening test was done and 7 of the workers had a mouth opening of less than 2, which is alarming and needs intervention. Oral premalignant lesions if not taken care of at the right time 70% of them are likely to become cancers!!

A need was felt that oral screening and tobacco cessation facilities be available for the workers and employees on the premises.

The program was a success and received positive feedback from the workers, who expressed their gratitude and appreciation for the opportunity to learn and benefit from such a useful and informative initiative.

The program was a part of IOCL’s and MAX’s ongoing efforts to promote and enhance the health and safety of the workers and their families and to contribute to the global fight against cancer. IOCL and MAX hope to continue and expand their programs on cancer and tobacco awareness and prevention in the future and to inspire and empower the workers and their families to lead healthy and happy lives.

Dr. Pawan Gupta MS. (Gen Surgery), M.Ch. (Surgical Oncology), FAIS, FSOG, CTCS

Sr. Director, Surgical Oncology, MAX Institute of Cancer Care, EZ-   Delhi NCR

           Founder Director – ICanCaRe, ICanCaRe Academy

Smokers with diabetes and hypertension at higher risk of Cardiovascular events

“Smokers with diabetes and hypertension at higher risk of Cardiovascular events”. – ICanCaRe

Introduction:

I continuation of our previous blog article on the risk of smoking and diabetes type 2, a recent article on a link of CVD with diabetes, highlights the need for a comprehensive smoking cessation program for such patients.

In the complex landscape of managing type 2 diabetes, the link between blood pressure levels and cardiovascular disease (CVD) mortality has emerged as a critical focal point. A recent study published in the Journal of the American Heart Association delves into the intricate relationship between systolic and diastolic blood pressure (BP) levels and their impact on mortality in patients with type 2 diabetes. The findings, drawn from a multi-institutional diabetes registry in Singapore, underscore the urgency for comprehensive interventions like ICanCaRe to address the cardiovascular risks associated with type 2 diabetes.

Unraveling the Study’s Objectives:

Led by Loraine Liping Seng and her colleagues, the study aimed to unravel the correlation between systolic and diastolic BP levels and the risk of CVD mortality in patients with type 2 diabetes. Additionally, the study explored associations with all-cause mortality, the composite outcome of all-cause mortality and CVD hospitalization, and the composite outcome of CVD mortality and hospitalization due to specific cardiovascular events such as myocardial infarction (MI), heart failure (HF), stroke, bypass surgery (CABG), and percutaneous coronary intervention (PCI).

The Singaporean Perspective:

Utilizing data from a multi-ethnic Asian patient pool – Chinese, Malay, and Indian – the study delved into a rich repository of information encompassing primary care to hospital-based care. The comprehensive analysis included 83,721 patients with type 2 diabetes over a span of seven years. Notably, almost 80% of the participants were on antihypertensive treatment, highlighting the prevalence of the condition in this population.

Key Findings and Implications:

The study’s primary outcome revealed a notable association between clinic systolic BP of 130 mm Hg or higher and/or diastolic BP of 90 mm Hg or greater with an increased risk of CVD mortality in patients with type 2 diabetes. Intriguingly, adverse cardiovascular outcomes were also paradoxically linked to diastolic blood pressure levels below 70 mm Hg. While the authors acknowledge the potential influence of reverse causality, the study emphasizes the importance of maintaining systolic BP below 130 mm Hg and diastolic BP below 90 mm Hg in individuals with type 2 diabetes.

ICanCaRe: A Holistic Approach to Cardiovascular and diabetic Health:

In light of these findings, the ICanCaRe Tobacco Intervention program takes center stage as a holistic approach to address the multifaceted challenges posed by type 2 diabetes. Recognizing the intricate interplay between cardiovascular health, diabetes, and other lifestyle factors, ICanCaRe empowers individuals to make informed choices and adopt a comprehensive approach to well-being. The ICanCaRe program is designed to offer personalized support to individuals seeking to quit Tobacco. Understanding that each journey is unique, the program tailors its strategies to meet each participant’s specific needs and challenges. (www.app.icancare.in). Medical assistance in a protocol-based approach is provided by Certified Tobacco Cessation Specialists. This multi-faceted ABCD approach for tobacco cessation ensures that individuals have access to all necessary resources to 100% quit smoking or Chewing tobacco.

Conclusion:

As the nexus between type 2 diabetes, blood pressure levels, and cardiovascular risks becomes clearer, interventions like ICanCaRe gain significance in the realm of patient care. By integrating the latest research findings into its framework, ICanCaRe supports tobacco cessation, guiding individuals through the complexities of managing diabetes and promoting cardiovascular health. In a world where data illuminates the path to better outcomes, the ICanCaRe program becomes an invaluable tool in the fight against the complications of type 2 diabetes with increased risk with smoking, offering a lifeline to those seeking a healthier, more empowered future.

Reference:

  1. Loraine Liping Seng, et al. Real-world systolic and diastolic blood pressure levels and cardiovascular mortality in patients with type 2 diabetes-results from a large registry cohort in Asia. J Am Heart Assoc. 2023 Nov 28:e030772. doi: 10.1161/JAHA.123.030772.
  2. World Health Organization, International Diabetes Federation, and the University of Newcastle. “Policy Brief on Smoking and Type 2 Diabetes.” This brief offers a comprehensive overview of the research linking smoking cessation to a reduced risk of type 2 diabetes.
  3. ICanCaRe. “Tobacco Cessation Program Overview.” www.icancare.in
  4. American Diabetes Association. “The Impact of Smoking on Diabetes and Diabetes Management.” This article discusses the implications of smoking on diabetes management and the benefits of cessation.
  5. National Institute of Diabetes and Digestive and Kidney Diseases. “Smoking and Diabetes.” This resource offers a deeper understanding of how smoking affects diabetes risk and control.
  6. ICanCaRe. (2021). ABCD of Tobacco Cessation. https://www.icancare.org/abcd.html

#icancare #diabetesandSmoking #smoking #quittobacco #icancareapp #CVDandsmoking

PRISm – A COPD Risk factor and Smoking Cessation advocated by ICanCaRe

Introduction:

Preserved Ratio Impaired Spirometry (PRISm) is a critical indicator characterized by an FEV1 of <80% predicted and a FEV1/FVC ratio of >0.70. Identified as a precursor to Chronic Obstructive Pulmonary Disease (COPD), PRISm demands careful monitoring, particularly in individuals with respiratory symptoms. The studies by Mariko Kogo et al. and Daniel H Higbee et al. shed light on the significant correlation between PRISm, respiratory symptoms, and the heightened risk of developing COPD, emphasizing the urgency for effective tobacco cessation interventions. In this context, the ICanCaRe tobacco cessation intervention program emerges as a beacon of hope, advocating for smoking cessation on an individual basis. (www.icancare.in). This blog is in series with the previous blog on Increased risk of Asthma in Children exposed to secondhand smoke.( ICanCaRe Blog) (ICanCaRe LinkedIn)

Understanding the PRISm Challenge:

PRISm, when associated with respiratory symptoms such as cough, sputum, and dyspnea, poses an independent risk factor for COPD development, especially in individuals with a history of smoking. Even without symptoms at baseline, PRISm can progress within five years, leading to airflow limitations. In addition, individuals with PRISm could exhibit increased respiratory symptoms, poor health-related quality of life, multiple comorbidities, and increased mortality compared with those with normal spirometry. The quantitative assessment capability of PRISm becomes a crucial tool for identifying and addressing the risks faced by smokers, reinforcing the need for smoking cessation.

The ICanCaRe Tobacco Cessation Intervention program quantifies the need for individuals and the digital protocol puts the urgency for smoking cessation on an individual basis.

ICanCaRe: A Holistic Approach to Tobacco Cessation:

ICanCaRe tobacco cessation wellness program stands out as a comprehensive, evidence-based tobacco cessation program aligned with the latest research findings. Grounded in the insights from studies by Kogo et al. and Higbee et al., ICanCaRe adopts a holistic approach to empower individuals to overcome addiction, ensuring long-term abstinence, and reducing the risk of respiratory complications.

Key Components of ICanCaRe – ABCD of Tobacco Cessation:

1. ACTIVE MOTIVATION: ICanCaRe actively motivates tobacco users through quantitative and qualitative assessments, estimating the progressive risk associated with continued smoking.

2. BEHAVIOR INTERVENTION: Tailored behavioral counseling strategies address unique triggers contributing to tobacco addiction, crucial for addressing psychological aspects and enhancing successful cessation.

3. COMORBIDITY MANAGEMENT: Clinical assessments for associated morbidities are conducted, with specialists providing personalized care.

4. DRUGS and MEDICATIONS – Pharmacotherapy: The program integrates evidence-based pharmacotherapies to manage withdrawal symptoms and cravings, enhancing the effectiveness of the intervention and ensuring complete cessation.

Call 011-43077695 or write to info@icancare.in and download the ICanCaRe tobacco Wellness APP (http://app.icancare.in)

Conclusion – Empowering Individuals for a Tobacco-Free Future:

As we confront the challenges posed by PRISm and its link to respiratory symptoms, the ICanCaRe Tobacco Cessation Intervention program stands as a beacon of hope. By integrating the latest research findings into its framework, ICanCaRe not only recognizes the severity of the issue but actively addresses it through a personalized and holistic approach. It serves as a call to action for individuals to take charge of their respiratory health, break free from tobacco addiction, and embrace a future free from the shackles of compromised lung function.

ICanCaRe stands at the forefront of the battle against tobacco addiction, offering a lifeline to those grappling with the consequences of PRISm. Through its holistic approach, the program not only supports individuals in their journey to quit smoking but also contributes to a healthier, tobacco-free future for communities worldwide.

It is time we #savetheyouth. SAVE our next generation!! #knowtobacco to #notobacco

Reference:

1. Mariko Kogo et al. Longitudinal changes and association of respiratory symptoms with preserved ratio impaired spirometry (PRISm): The Nagahama Study. Ann Am Thorac Soc. 2023 Nov;20(11):1578-1586. doi: 10.1513/AnnalsATS.202301-050OC.

2. Daniel H Higbee et al. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis. Lancet Respir Med. 2022 Feb;10(2):149-157. doi: 10.1016/S2213-2600(21)00369-6.

Author –

1. Dr Shikha Jindal Consultant Pulmonologist Dr Shikha Jindal Gupta MD, CTCS(GU)

– Sr Consultant Pulmonologist,

– Certified Tobacco Cessation Specialist (Gujarat University by ICanCaRe)

Neo Super-Speciality Hospital, Noida

2. Dr Pawan Gupta M.Ch. Cancer Surgeon

 –  Sr. Director, Surgical Oncology

MAX Institute of Cancer Care, Vaishali, Patparganj and Noida

–          Founder Director – ICanCaRe – Innovative Cancer Care and Rehabilitation ICanCaRe, ICanCaRe Academy

–          Master Trainer – Tobacco Cessation Courses, Oral Cancers

#icancare #asthmaawareness #secondhandsmoke #icancareapp #pawangupta #icancareacademy #knowtobacco #Prism #COPD #smoking #quitsmoking

Suneela Garg Dr. Paramita Sengupta Rakesh Gupta Dr Pawan Gupta Dr REENA R KUMAR Shruti Agrawal Rishabh Agrawal Dr. Siddhi Hathiwala Dr Neha Agrawal ICanCaRe – Innovative Cancer Care and Rehabilitation Dr Shikha Jindal Consultant Pulmonologist